Cummings, Jeffrey http://orcid.org/0000-0001-8944-4158
Funding for this research was provided by:
National Institute of General Medical Sciences (P20GM109025)
National Institute on Aging (R01AG053798, P20AG068053, P30AG072959, R35AG71476)
National Institute of Neurological Disorders and Stroke (U01NS093334)
Article History
Accepted: 5 March 2023
First Online: 15 April 2023
Declarations
:
: JC is supported by NIGMS grant P20GM109025; NINDS grant U01NS093334; NIA grant R01AG053798; NIA grant P20AG068053; NIA grant P30AG072959; NIA grant R35AG71476; Alzheimer’s Disease Drug Discovery Foundation (ADDF); Ted and Maria Quirk Endowment; and the Joy Chambers-Grundy Endowment. No payment was received for the preparation of this article.
: JC has provided recent (past year) consultation to Acadia, Actinogen, Acumen, AlphaCognition, AriBio, Artery, Biogen, Cassava, Cerecin, Corium, Diadem, EIP Pharma, Eisai, Genentech, GAP Innovations, Janssen, Karuna, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Otsuka, PRODEO, Prothena, ReMYND, Resverlogix, Roche, Signant Health, Simcere, Sunbird Bio, Suven, TrueBinding, and Vaxxinity pharmaceutical, assessment, and investment companies.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Dr. Cummings is the sole author and responsible for all aspects of the document.